101 related articles for article (PubMed ID: 10765095)
1. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E
Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095
[TBL] [Abstract][Full Text] [Related]
2. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
[TBL] [Abstract][Full Text] [Related]
3. Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Mandalà M; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Confalonieri G; Malugani F; Moro C; Fumagalli G; Giani L; Tancini G
Tumori; 1999; 85(6):494-7. PubMed ID: 10774572
[TBL] [Abstract][Full Text] [Related]
4. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Fine SA; Frohman LA
J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.
Méndez I; Alcocer-Varela J; Parra A; Lava-Zavala A; de la Cruz DA; Alarcón-Segovia D; Larrea F
Lupus; 2004; 13(1):45-53. PubMed ID: 14870917
[TBL] [Abstract][Full Text] [Related]
6. Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis.
Delitala G; Masala A; Alagna S; Devilla L
Biomedicine; 1976 Jul; 25(5):173-6. PubMed ID: 1000028
[TBL] [Abstract][Full Text] [Related]
7. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
[TBL] [Abstract][Full Text] [Related]
8. Dynamic evaluation of prolactin secretion in essential hypertension: evidence against hypothalamic-pituitary dopaminergic dysfunction.
Lengyel AM; Vieira JG; Chacra AR; Abucham-Filho JZ; Lima MP; Ribeiro AB; Ramos OL
J Clin Endocrinol Metab; 1982 Apr; 54(4):849-53. PubMed ID: 6801072
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
[TBL] [Abstract][Full Text] [Related]
10. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
Rao R; Scommegna A; Frohman LA
Am J Obstet Gynecol; 1982 Aug; 143(8):883-7. PubMed ID: 7102764
[TBL] [Abstract][Full Text] [Related]
11. L-DOPA attenuates prolactin secretion in response to isolation stress in Holstein steers.
Kasuya E; Yayou K; Sutoh M
Anim Sci J; 2013 Jul; 84(7):562-8. PubMed ID: 23607456
[TBL] [Abstract][Full Text] [Related]
12. Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.
Espinós JJ; Vanrell C; Gich I; Urgell E; Calaf J
Gynecol Endocrinol; 2017 Feb; 33(2):148-151. PubMed ID: 27841032
[TBL] [Abstract][Full Text] [Related]
13. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects.
Anderson PW; Malarkey WB; Salk J; Kletsky OA; Hsueh WA
J Clin Endocrinol Metab; 1989 Sep; 69(3):518-22. PubMed ID: 2503532
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Vigan P; Strada G
Int J Biol Markers; 2005; 20(2):123-125. PubMed ID: 28207138
[TBL] [Abstract][Full Text] [Related]
16. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependency and reproducibility of the prolactin response to metoclopramide.
Kitaoka M; Takebe K; Kobayashi M; Nakazono M; Kudo M
Horm Metab Res; 1980 Apr; 12(4):155-8. PubMed ID: 6771199
[TBL] [Abstract][Full Text] [Related]
18. The effect of L-dopa and chlorpromazine on prolactin and growth hormone secretion in normal women.
Leblanc H; Yen SS
Am J Obstet Gynecol; 1976 Sep; 126(2):162-4. PubMed ID: 961756
[TBL] [Abstract][Full Text] [Related]
19. [The effects of l-dopa administration on the prolactin levels in short-stature subjects].
Saggese G; Cesaretti G; Carlotti C; Cioni C; Bracaloni C
Minerva Pediatr; 1992 Mar; 44(3):73-8. PubMed ID: 1518496
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
